MedKoo Cat#: 208485 | Name: LUNA18
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

LUNA18 is an 11-mer cyclic peptide KRAS inhibitor for the intracellular tough target RAS.

Chemical Structure

LUNA18
LUNA18
CAS#2676177-63-0

Theoretical Analysis

MedKoo Cat#: 208485

Name: LUNA18

CAS#: 2676177-63-0

Chemical Formula: C73H105F5N12O12

Exact Mass: 1436.7895

Molecular Weight: 1437.71

Elemental Analysis: C, 60.99; H, 7.36; F, 6.61; N, 11.69; O, 13.35

Price and Availability

Size Price Availability Quantity
1mg USD 1,950.00 2 Weeks
50mg USD 6,950.00 2 months
100mg USD 9,950.00 2 months
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
luna18; luna-18; luna 18; paluratidum; paluratide
IUPAC/Chemical Name
2-((5S,8S,11S,14S,17S,22aS,28S,34S,36aS)-8-((S)-sec-Butyl)-17-cyclopentyl-28-(3,5-difluoro-4-(trifluoromethyl)phenethyl)-35-ethyl-11-isobutyl-5,6,12,15,18,32-hexamethyl-34-(4-methylbenzyl)-4,7,10,13,16,19,22,27,30,33,36-undecaoxotetratriacontahydro-2H-spiro[azeto[1,2-a]pyrrolo[1,2-m][1,4,7,10,13,16,19,22,25,28,31]undecaazacyclotritriacontine-20,1'-cyclopentan]-14-yl)-N,N-dimethylacetamide
InChi Key
CBRJDSIKAVHFFO-DEBTURSASA-N
InChi Code
InChI=1S/C73H105F5N12O12/c1-15-44(6)60-69(100)84(11)45(7)64(95)90-35-31-53(90)68(99)88(16-2)56(39-46-27-25-43(5)26-28-46)66(97)83(10)41-57(91)79-51(30-29-47-37-49(74)59(50(75)38-47)73(76,77)78)65(96)89-34-21-24-52(89)63(94)81-72(32-19-20-33-72)71(102)87(14)61(48-22-17-18-23-48)70(101)86(13)55(40-58(92)82(8)9)67(98)85(12)54(36-42(3)4)62(93)80-60/h25-28,37-38,42,44-45,48,51-56,60-61H,15-24,29-36,39-41H2,1-14H3,(H,79,91)(H,80,93)(H,81,94)/t44-,45-,51-,52-,53-,54-,55-,56-,60-,61-/m0/s1
SMILES Code
O=C(N(C)C)C[C@@H](C(N(C)[C@@H](CC(C)C)C(N[C@@H]([C@@H](C)CC)C(N(C)[C@H]1C)=O)=O)=O)N(C)C([C@H](C2CCCC2)N(C)C(C3(CCCC3)NC([C@@](CCC4)([H])N4C([C@H](CCC5=CC(F)=C(C(F)(F)F)C(F)=C5)NC(CN(C)C([C@H](CC6=CC=C(C)C=C6)N(CC)C([C@@](CC7)([H])N7C1=O)=O)=O)=O)=O)=O)=O)=O
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 1,437.71 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Ohta A, Tanada M, Shinohara S, Morita Y, Nakano K, Yamagishi Y, Takano R, Kariyuki S, Iida T, Matsuo A, Ozeki K, Emura T, Sakurai Y, Takano K, Higashida A, Kojima M, Muraoka T, Takeyama R, Kato T, Kimura K, Ogawa K, Ohara K, Tanaka S, Kikuchi Y, Hisada N, Hayashi R, Nishimura Y, Nomura K, Tachibana T, Irie M, Kawada H, Torizawa T, Murao N, Kotake T, Tanaka M, Ishikawa S, Miyake T, Tamiya M, Arai M, Chiyoda A, Akai S, Sase H, Kuramoto S, Ito T, Shiraishi T, Kojima T, Iikura H. Validation of a New Methodology to Create Oral Drugs beyond the Rule of 5 for Intracellular Tough Targets. J Am Chem Soc. 2023 Nov 8;145(44):24035-24051. doi: 10.1021/jacs.3c07145. Epub 2023 Oct 24. PMID: 37874670. 2: Tanada M, Tamiya M, Matsuo A, Chiyoda A, Takano K, Ito T, Irie M, Kotake T, Takeyama R, Kawada H, Hayashi R, Ishikawa S, Nomura K, Furuichi N, Morita Y, Kage M, Hashimoto S, Nii K, Sase H, Ohara K, Ohta A, Kuramoto S, Nishimura Y, Iikura H, Shiraishi T. Development of Orally Bioavailable Peptides Targeting an Intracellular Protein: From a Hit to a Clinical KRAS Inhibitor. J Am Chem Soc. 2023 Aug 2;145(30):16610-16620. doi: 10.1021/jacs.3c03886. Epub 2023 Jul 18. PMID: 37463267. 3: Nomura K, Hashimoto S, Takeyama R, Tamiya M, Kato T, Muraoka T, Kage M, Nii K, Kotake K, Iida S, Emura T, Tanada M, Iikura H. Broadly Applicable and Comprehensive Synthetic Method for N-Alkyl-Rich Drug-like Cyclic Peptides. J Med Chem. 2022 Oct 13;65(19):13401-13412. doi: 10.1021/acs.jmedchem.2c01296. Epub 2022 Sep 15. PMID: 36109865.